These findings position JMJD8 as a dual-axis regulator of immunosuppression and reveal its targeting combined with anti-PD-1/PD-L1 blockade as a rational strategy to reverse immune evasion and enhance therapeutic efficacy in breast cancer models. Here, PDCD1 is linked to breast cancer.